ES2168581T3 - Derivados de indazol sustituidos. - Google Patents

Derivados de indazol sustituidos.

Info

Publication number
ES2168581T3
ES2168581T3 ES97304083T ES97304083T ES2168581T3 ES 2168581 T3 ES2168581 T3 ES 2168581T3 ES 97304083 T ES97304083 T ES 97304083T ES 97304083 T ES97304083 T ES 97304083T ES 2168581 T3 ES2168581 T3 ES 2168581T3
Authority
ES
Spain
Prior art keywords
sub
formula
compounds
invention refers
derivatives replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97304083T
Other languages
English (en)
Inventor
Anthony Marfat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2168581T3 publication Critical patent/ES2168581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA Y A SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE LA LINEA DISCONTINUA EN LA FORMULA I INDICA UN ENLACE SENCILLO O DOBLE Y EN LA QUE R, R{SUB,1}, X{SUB,1} Y X{SUB,2} SON COMO SE HA DEFINIDO EN LA PRESENTE. LA INVENCION SE REFIERE ADEMAS A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS COMPUESTOS DE FORMULA I Y A LOS METODOS DE INHIBICION DE LA FOSFODIESTERASA DE TIPO IV O LA PRODUCCION DEL FACTOR DE NECROSIS TUMORAL EN UN MAMIFERO MEDIANTE LA ADMINISTRACION DE LOS COMPUESTOS DE FORMULA I A DICHO MAMIFERO.
ES97304083T 1996-06-27 1997-06-11 Derivados de indazol sustituidos. Expired - Lifetime ES2168581T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2107296P 1996-06-27 1996-06-27

Publications (1)

Publication Number Publication Date
ES2168581T3 true ES2168581T3 (es) 2002-06-16

Family

ID=21802182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97304083T Expired - Lifetime ES2168581T3 (es) 1996-06-27 1997-06-11 Derivados de indazol sustituidos.

Country Status (8)

Country Link
US (1) US5958953A (es)
EP (1) EP0816357B1 (es)
JP (1) JP3032840B2 (es)
AT (1) ATE211740T1 (es)
CA (1) CA2208792C (es)
DE (1) DE69709493T2 (es)
ES (1) ES2168581T3 (es)
MX (1) MX9704856A (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CA2264798A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6391872B1 (en) * 1997-11-04 2002-05-21 Pfizer Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
DK1436427T3 (da) * 2001-10-19 2008-12-08 Chru Tours Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
EP1807082A4 (en) * 2004-10-26 2010-12-01 Janssen Pharmaceutica Nv INHIBITOR COMPOUNDS OF XA FACTORS
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
ES2663870T3 (es) * 2005-09-22 2018-04-17 Huntsman International Llc Método para la producción de poliisocianatos
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
WO2010120854A1 (en) * 2009-04-15 2010-10-21 Glaxosmithkline Llc Chemical compounds
WO2012026511A1 (ja) * 2010-08-27 2012-03-01 協和発酵キリン株式会社 医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034098B2 (ja) * 1981-01-29 1985-08-07 富士写真フイルム株式会社 ハロゲン化銀カラ−感光材料の処理方法
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
DE69709493D1 (de) 2002-02-14
JP3032840B2 (ja) 2000-04-17
CA2208792C (en) 2002-12-10
US5958953A (en) 1999-09-28
ATE211740T1 (de) 2002-01-15
CA2208792A1 (en) 1997-12-27
JPH1072445A (ja) 1998-03-17
MX9704856A (es) 1998-06-30
EP0816357B1 (en) 2002-01-09
EP0816357A1 (en) 1998-01-07
DE69709493T2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2168581T3 (es) Derivados de indazol sustituidos.
PA8432301A1 (es) Analogos de indazol sustituido.
PA8437301A1 (es) Derivados de indazol
CR6643A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
UY27350A1 (es) Azaindoles
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
CO4650038A1 (es) Derivados del indazol sustituidos y compuestos relacionados
ES2178724T3 (es) Acidos arilsulfonamido hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral alfa y de metaloproteinasas de matriz.
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
ES2161290T3 (es) Derivados de quinazolina.
PA8442201A1 (es) Derivados de 6-fenilpiridil-2-amina
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
ES2113867T3 (es) Imino-derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
UY26782A1 (es) Derivados del benzotiazol
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
UY27592A1 (es) Nuevo uso
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
CL2022003646A1 (es) Derivados de amidopirimidona
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 816357

Country of ref document: ES